Prognostic Applications Are Growing Rapidly for Cancer Biomarkers


The number of publications that describe novel biomarkers for cancer has grown by an average of 24% over the last 5 years. As previously reported, this growth rate is essentially the same as for novel biomarkers across all diseases.

This isn’t surprising since 26% of the nearly 4,000 clinical biomarkers listed in BiomarkerBase are being used or developed in the Oncology therapeutic area.

Percent of All Biomarkers in BiomarkerBase Being Used in Each Therapeutic Area

Within cancer biomarkers there is a significant difference in the recent growth rates for novel diagnostic versus prognostic biomarkers.

During 2014, a novel cancer diagnostic biomarker is being published about once every 4-5 days, which is basically the same rate as for 2013.

Novel prognostic biomarkers, however, are being published at a rate 50% higher than 2013. As for all novel biomarkers, the number of new prognostic biomarkers for cancer published during 2014 has nearly surpassed the total for all of 2014.

Total Number of Publications Annually That Describe Novel Prognostic Biomarkers for Cancer
This chart shows the total number of publications annually since 2005 that include the words “novel biomarker” OR “new biomarker” AND “cancer” AND “prognostic” in the title, abstract, or body text. The total for 2014 is as of August 29, 2014.

Since there are so many innovative therapies being developed and used for cancer it is encouraging that there are a rapidly increasing number of biomarkers able to describe the effectiveness of those therapies.


Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access